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Abstract 
 
Historically, phase II oncology trials assessed a treatment’s efficacy by examining its tumor 
response rate in a single-arm trial. Then, approximately 25 years ago, certain statistical and 
pharmacological considerations ignited a debate around whether randomized designs 
should be utilized instead. Here, based upon an extensive literature review, we review the 
arguments on either side of this debate. In particular, we describe the numerous factors that 
relate to the reliance of single-arm trials on historical control data, and detail the trial 
scenarios in which there was general agreement on preferential utilization of single-arm or 
randomized design frameworks, such as the use of single-arm designs when investigating 
treatments for rare cancers. We then summarize the latest figures on phase II oncology trial 
design, contrasting current design choices against historical recommendations on best 
practice. Ultimately, we find several ways in which the design of recently completed phase II 
trials does not appear to align with said recommendations. For example, despite advice to 
the contrary, only 66.2% of the assessed trials that employed progression-free survival as a 
primary or co-primary outcome used a randomized comparative design. In addition, we 
identify that just 28.2% of the considered randomized comparative trials came to a positive 
conclusion, as opposed to 72.7% of the single-arm trials. We conclude by describing a 
selection of important issues influencing contemporary design, framing this discourse in 
light of current trends in phase II, such as the increased use of biomarkers and recent 
interest in novel adaptive designs. 
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Classical phase II oncology trial design 
The classical paradigm of oncological drug development comprises three phases of clinical 
trials. In phase I, a treatment’s toxic effects are assessed and the recommended dose(s) for 
subsequent trials determined. Phase II provides the first assessment of a regimen’s efficacy, 
with success typically resulting in a confirmatory phase III trial being conducted. Phase II 
trials thus play a pivotal role, providing the principal evidence for deciding whether to carry 
out a large phase III trial. The consequences of an incorrect decision at this time can be far-
reaching: halting the development of an effective regimen could deprive future patients of a 
valuable treatment option, whilst continuing to develop a futile regimen could waste 
substantial resources. Accordingly, the optimal approach to conducting phase II trials has 
received much attention. 
Historically, given the scarcity of effective anti-cancer agents in the 1950s, the 
accepted perspective was that phase II should act as a screening process to efficiently weed 
out inactive regimens [1,2]. For this, a short-term surrogate endpoint for long-term clinical 
benefit was required. A binary tumor response indicator, later formally defined via RECIST 
[3], became the endpoint of choice [2]. Furthermore, Gehan offered in 1961 a design that 
would long remain the primary approach to phase II oncology trial design [1]. Based upon 
the belief of the day that a response rate of less than 20% was not promising, he 
recommended that 14 patients be recruited and observed for tumor response. If no 
response was observed, this would ascertain with 95% confidence that the true response 
rate was below 20%. With at least one response observed, a second stage of recruitment 
and observation would be conducted to accurately estimate the true response rate. 
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Unfortunately, Gehan’s design provided no guidance on whether the observed 
response rate was clinically meaningful. Consequently, as the number of available effective 
oncology drugs increased during the 1970s, phase II trials shifted to demand a higher 
standard of evidence of potential clinical benefit [2]. The prevailing techniques for achieving 
this were Simon’s two-stage single-arm designs [4], which were constructed to allow a 
formal hypothesis test to be conducted on the tumor response rate. Simon’s designs, like 
Gehan’s, experienced a sustained period of time as the preferred approach in phase II. Thus, 
unlike in many disease settings, phase II cancer trials were traditionally non-randomized. 
Moreover, they almost all used tumor response as their primary outcome [5]. By the mid-
1990s, however, questions over the optimality of this convention began to arise. 
In this article, we focus on these questions, in particular examining opinions on the 
role of randomization in phase II. To provide a comprehensive overview of this subject, we 
base our discourse on a completed narrative literature review (see Supplementary Methods 
and Supplementary Tables 1-5 for details on this review). We proceed by describing one of 
the primary reasons for the now evident changes in phase II design. We then discuss the 
arguments put forth for and against the use of randomization, along with the real-world 
evidence and statistical investigations that complicate this debate. Our discourse then turns 
to consider the current design of phase II oncology trials, and how such design aligns with 
past opinions on best practice. We conclude by highlighting current issues that are likely to 
influence changes in the design of future phase II trials. 
 
Changing phase II design: molecularly targeted agents suggest a new paradigm is needed 
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Arguably the principal driver of change in phase II oncology trial design was the advent of 
molecularly targeted agents (MTAs). Classic anti-cancer agents were cytotoxic, thus it was 
considered reasonable to assess their efficacy via their ability to shrink tumors, and the fact 
that tumors do not typically spontaneously shrink meant many accepted the lack of a 
randomized comparator arm. However, it was anticipated that the new MTAs may often be 
cytostatic; delaying tumor progression, rather than leading to tumor shrinkage [6,7]. 
Accordingly, it was feared that the use of tumor response as a primary endpoint may lead to 
many novel regimens, which do increase clinical benefit, being rejected from further 
consideration [8-11]. Thus, it was contended that a new approach was required in phase II 
for cytostatic agents. 
Initially, the proposed approaches varied greatly, with some authors even suggesting 
that phase II be skipped [12]. Unsurprisingly, such suggestions were not widely favored. It 
was acknowledged that whilst this may seem a desirable means of reducing development 
plan sample sizes, the ever-rising cost of phase III studies, and the scarcity of available 
patients to enroll in trials, would make it impossible to test all regimens in this manner 
[9,13,14]. Further, given a preliminary efficacy assessment could be acquired in phase II 
using a relatively small number of subjects, it would be unethical to expose large numbers of 
patients to a regimen for which little evidence of efficacy exists [9]. 
More reasonably, calls for the use of an alternative primary endpoint in phase II trials 
of cytostatic agents soon grew [13,15]. In particular, progression-free survival (PFS) was 
much advocated, as an assessment of time until disease progression would more accurately 
capture the benefits of cytostatic agents. Furthermore, PFS, it was argued, would be more 
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efficient to estimate than overall survival and would not be affected by salvage treatment. 
However, PFS is highly dependent on a disease’s natural history. It was thus contended that 
with this necessary change in endpoint, so came a necessary change in design to utilize 
randomization [11,16-19]. With this, one of the primary reasons randomization has been 
advocated for in phase II was apparent. 
 
Arguments for and against the use of randomization in phase II 
Along with changes proposed to phase II design because of the rise of MTAs, appeals for the 
use of randomization no matter the regimen under investigation, or the chosen primary 
endpoint, also increased. Here, we discuss the arguments for and against randomization 
that have appeared in the literature, providing an overview in Table 1. Note that we 
concentrate our discussion on randomization as a means to formally comparing treatments 
using a hypothesis test, as the majority of articles have focused on the use of randomization 
for this purpose. Thus, for brevity when we now refer to randomized designs, we mean 
randomized comparative designs. However, many of the following points are also relevant 
to a debate on the utility of randomized non-comparative designs. 
At the center of most discussions on phase II design has been the key assumption of 
a single-arm trial: the historical controls used to design the current study provide a fair 
representation of the probable outcome for patients in the new trial, if they were given the 
same control treatment. Many have noted that due to improvements in the standard of 
care, earlier detection rates, institutional variabilities, and differences in prognostic factors, 
only in rare scenarios would historical controls provide such a representation [20-23]. 
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Potential differences in prognostic factors between historical controls and 
concurrent participants was seen as particularly problematic, as it was well-recognized that 
unknown prognostic factors can profoundly affect a single-arm trial’s error-rates [23,24]. A 
modelling-based approach was suggested as a possible solution to accounting for such 
prognostic variables [25]. However, whilst proponents of randomization acknowledged that 
this could improve upon simple unadjusted comparisons to historical controls, given the 
majority of inter-individual variability remains unexplained after accounting for all measured 
predictors [8,16,26,27], they argued that such adjustment procedures were not widely 
applicable or reliable [20,26]. So too did others note that the desire for a new agent to ‘look 
good’ could manifest itself in setting the historical response rate too low [28,29], or the 
enrollment only of patients who ‘look promising’ [30]. Each of these problems, it was 
maintained, would not be an issue in a randomized trial [17,18,20,22-24,26,30-33]. 
Nonetheless, numerous publications still argued in favor of single-arm designs 
[23,34-37], claiming that they can be readily utilized given high enough confidence in the 
historical data [23,34]. A melanoma overall survival database was in particular a heralded 
means through which successful single-arm studies had been conducted [25]. In addition, 
those in favor of single-arm designs noted flaws in the supposed advantages of 
randomization, arguing that the purported ability of randomized phase II trials to balance 
prognostic factors was an illusion, as the majority of such trials used simple randomization, 
which would be unlikely to provide balance for typical phase II sample sizes [23,36,38-40]. 
Moreover, as was feared about single-arm trials, randomized phase II trials could also 
feature highly selected patients [17], and easily fall foul of differential loss to follow-up or 
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patient drop-out [41]. As a counterpoint, it was argued that randomization was a better way 
to handle many sources of bias, and actually the only way to make detection and 
quantification of imbalances possible [23]. 
Randomized phase II trials have also been viewed as troubling because of the 
possibility that investigators will mistakenly treat their results as though they are from a 
phase III trial [42]; a claim arguably supported by the large number of comparisons 
performed at the end of non-comparative trials [38]. This though, others claimed, should 
not be an argument against randomization, and in fact a highly statistically significant p-
value from a randomized phase II trial could provide enough evidence for a licensing claim, 
which is not in general possible from a single-arm study [23]. 
Perhaps the most common argument against randomizing was its associated cost 
and complexity, with many fearful of the resultant requisite sample size, the fact that 
randomized trials can be more complex for patients to understand, and that it may be 
difficult to find patients willing to be randomized [23,34,35]. This viewpoint was supported 
by a review that found 27% of conducted randomized phase II studies had encountered 
‘sizeable problems’ [23]. Those in favor of randomization, however, argued that in general 
randomization would provide more reliable data [8], and since ‘you get what you pay for’ 
[33] the increased cost should be accepted [13]. Furthermore, this argument ignored the 
fact that randomizing in phase II could decrease the cost of a project overall [20,26,43], and 
that whilst it may seem appealing to utilize single-arm trials to develop drugs quickly, or to 
allow expedient publication, in the long term we all had more to gain from well-designed, 
randomized phase II trials [33]. 
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djz126/5520955 by C
ardiff U
niversity user on 23 July 2019
Advocates of randomization further attacked the issue of larger requisite sample 
sizes by arguing for one-sided hypothesis tests and allowance for increased type-I error-
rates [9,14,16,17,20,29]. Given the purpose of phase II is to screen and select, this was 
claimed to be entirely appropriate [16], and also logical for ethical reasons [17]. As a 
counterpoint, it was noted that the advantages of increasing error-rates to reduce sample 
sizes in phase II are negated by the cost associated with conducting more phase III trials with 
inactive agents. However, pro-randomization researchers contended that some control is 
better than none and highlighted that the type-I error-rate in single-arm trials is actually 
unknown [23,26]. 
Arguments in favor of single-arm designs were also made on ethical grounds, with 
some desiring to provide all enrolled patients with the experimental regimen [34]. Others, 
though, stated that randomizing may be more ethical, as the experimental treatment could 
be inferior [26], contending that in most cases there is equipoise [33]. 
Several authors were critical of the approach randomization implies about our 
method of identifying new treatments. Most prominently, Stewart and Kurzrock argued that 
using randomized designs in phase II to balance for characteristics that might confound 
efficacy assessment is the antithesis of personalized medicine, and that unless the target 
required for drug activity is very common or we know for each patient whether their tumor 
expressed the required target, randomization could produce misleading results [44]. This 
argument, though, was not logical to all, with it noted that any experienced group of 
investigators would identify a subgroup of patients with exceptional outcomes within a 
randomized trial [33]. 
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Finally, it is important to note that deliberations on what should become the typical 
primary endpoint in a phase II trial have long inter-weaved the debate around 
randomization; a consequence of a desire for improved endpoints to select treatments upon 
[10,45-50]. Here, though, we have limited our discussions to our primary interest: the 
suitability of single-arm designs in phase II. For an in-depth history of endpoints that could 
be utilized in oncology trials, we refer the reader to Wilson et al. [51]. 
 
Practical evidence on the outcome of utilizing randomized or non-randomized designs 
Along with the discussions outlined above, several authors have provided evidence on the 
result of utilizing different design frameworks in phase II, in practice. In particular, much 
evidence has suggested that the classical approach has contributed to the failure of phase II 
trials to predict long-term survival benefits. Kola and Landis [52] highlighted that 60% of 
regimens that had ‘promising’ activity in single-arm phase II trials failed to demonstrate 
superiority in phase III. Zia et al. [53] identified that response rates were regularly lower in 
phase III trials than in their preceding phase II studies. Maitland et al. [54] analyzed all phase 
II combination therapy trials published in 2001-02 and found that despite 72% being 
deemed successful, the likelihood that an ensuing trial would demonstrate important effects 
within 5 years was only 3.8%. Ratain [55] pointed to the extremely low positive predictive 
value of classical phase II trials. Finally, Vickers et al. [29] identified that 46% of surveyed 
phase II studies that required historical data, did not cite the source of this data. Even more 
troubling was their finding that those trials that failed to cite prior data suitably were more 
likely to declare an agent to be active. For many, this was evidence that a higher bar now 
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needed to be set for progressing to phase III. The solution to attaining this higher bar, it was 
argued, was randomization in phase II [13,17,20,30,33,56]. 
Complicating the picture, though, were the many results that favored the use of 
single-arm designs and tumor response. Goffin et al. [57] identified that higher overall 
response rates in phase I and II were predictive of regulatory approval in a range of cancer 
types. Moreover, El-Maraghi and Eisenhauer [50] established, in 89 surveyed phase II trials, 
higher response rates were predictive of regulatory approval for MTAs. Tsimberidou et al. 
[58] noted that of 31 drugs approved in 1973-2006 without a randomized trial, 30 remained 
fully approved. Finally, Chan et al. [59], in examining all phase III trials of targeted therapies 
against advanced cancers from 1985-2005 and their preceding phase II studies, found that 
randomization in phase II was not more likely to lead to a positive phase III result. 
Consequently, it was argued that success issues in phase III were not due to the use 
of single-arm trials in phase II, but to how these trials were planned and interpreted, and 
thus we should focus on conducting high quality single-arm trials [23]. Not all were 
convinced by these presentations however [20,60], with Gan et al. [23] in particular noting 
that such reviews are biased as many trials are never published, and it is likely that a higher 
proportion of randomized phase II trials would be published because of their greater 
intrinsic value. 
 
Statistical investigations of randomized and non-randomized design operating 
characteristics 
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Thus, arguments for and against classical phase II designs could readily be made based upon 
the available evidence from design use in practice. Hoping to clarify purely statistical 
recommendations, several publications have provided quantitative figures on optimal phase 
II design. 
Firstly, Mariani and Marubini noted that the error-rates of single-arm, but not 
randomized trials, are highly sensitive to the historical control rate assumptions [61]. Baey 
and Le Deley conducted a similar analysis and argued in favor of randomized designs [62]. 
Providing a less favorable view of randomization, Sharma et al. [63] re-sampled data from a 
positive and a negative phase III trial. They considered a variety of endpoints and designs, 
finding that randomized designs performed better for PFS at predicting a positive result for 
the positive trial, but that they had a higher false-negative rate for the negative trial. 
Taylor et al. [64] compared single-arm and randomized designs using a simulation 
study. They found that a randomized design of equal size to a single-arm trial made the 
correct decision more often, and that increasing the sample size was more beneficial to 
randomized than to single-arm trials. They concluded that in the presence of uncertainty 
around the historical response rate, and when a larger sample size is possible, a randomized 
design should be used. Similarly, Tang et al. [65] simulated single-arm and randomized 
phase II trials using data from a colorectal cancer study. They found that the false positive 
rate of single-arm trials was 2-4 times higher under modest drift of several considered 
patient selection factors, but that randomized phase II trials came at a cost of 2-4 times the 
sample size. They also argued that given enough patients, a randomized design was 
preferable. Sambucini later came to similar conclusions, having taken a Bayesian approach 
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to design comparison [66]. However, Pond and Abassi [67], using a simulation study that 
modelled numerous potential sources of variability, argued that single-arm and randomized 
designs were both warranted in certain circumstances. 
 
Consensus opinions on phase II design 
Thus, in spite of much debate, no consensus on the optimal design of phase II trials 
emerged. Nonetheless, several areas of general agreement are apparent; being for the most 
part described in two articles released following committee discussions [68,69], and in a 
table provided by Gan et al. [23]. In particular, it was widely accepted that both single-arm 
and randomized designs have a part to play in phase II [23,37,69-71], with it typically agreed 
that the number of randomized phase II trials should increase and PFS should become the 
conventional endpoint of choice [37]. 
Most authors believed that single-arm trials were acceptable for single, especially 
novel, agents when tumor response was expected [17,19,23,69]. They would also be useful 
for rare cancer types, where it may be challenging to enroll enough patients to conduct a 
randomized trial [23,34,72], in late disease and salvage settings, and when no standard 
treatment exists [68,69]. Additionally, if data suggested a response rate that was 
dramatically higher than that for available therapies, we may forego randomization [72]. 
They could also be logical in, the admittedly rare, situations in which a robust historical 
database exists [68]. 
In contrast, randomized designs would be required for combination therapies, as it 
would otherwise be difficult to distinguish the contribution of the experimental agent from 
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the established component [14,68,73]. They would be needed for time-to-event endpoints 
[3,17,23,69], when there is a lack of available suitable historical data [9,68,72], or when the 
target population is unclear or heterogeneous [69,74,75]. However, investigators were 
cautioned against conducting small randomized trials, with it propositioned that in general 
we may need to accept an increase in the size of phase II trials [68]. 
Finally, many papers agreed that alternative endpoints, outside of tumor response, 
should be given greater consideration, and ultimately be deployed in randomized trials 
[68,70]. Nonetheless, it was also well-recognized that although they were promising, many 
alternative endpoints required additional evaluation and validation before they could be 
utilized as primary outcomes in phase II [76], and thus the choice in practice would often 
remain between tumor response and PFS. 
 
Figures on the contemporary design of phase II oncology trials 
The number of available phase II designs is now extensive, with an overview of many 
provided by Brown et al. [77]. Consequently, several articles have sought to examine how 
frequently particular designs have been utilized. Together, they provide evidence that 
arguments for the increased use of randomization have permeated through to practice. 
Mariani and Marubini found that of 308 phase II trials published in 1997, only 4 (1.3%) were 
controlled [5], whilst Stone et al. examined publications in the Journal of Clinical Oncology 
between 1999 and June 2003 and identified only 23 randomized phase II trials out of 
approximately 250 studies [16]. However, Rubinstein et al. noted in 2011 that 69 (28%) of 
the then active National Cancer Institute sponsored phase II trials were randomized [19]. In 
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addition, Thezenas et al. [78], Ivanova et al. [79], and Langrand-Escure et al. [80] have all 
since conducted reviews of phase II trials, each identifying a large proportion incorporated 
randomization. 
Here, we focus on re-analyzing the data from Langrand-Escure et al. [80], who 
examined 557 trials published in three top oncology journals from 2010-2015. In Table 2 we 
present an assessment of several design characteristics, by design type: single-arm, multi-
arm non-randomized, randomized non-comparative, and randomized comparative studies, 
which form the main types of design in this dataset. Whilst in Table 3 we summarize the 
choice of primary and co-primary endpoints by the type of treatment under investigation. 
Our analyses reveal several important figures in relation to the aforementioned opinions on 
best-practice. We provide a summary of these in Box 1. 
Firstly, against prevailing opinion, a smaller proportion of targeted therapies were 
tested using randomized comparative designs (13.7%) than cytotoxic therapies (23.1%), and 
102 (32.4%) of the single-arm trials were of combination therapies (Table 2). 
Recommendations on the utilization of randomization with PFS appear to have been better 
heeded, with 47 (66.2%) of the trials employing PFS as a primary or co-primary outcome 
being randomized comparative. However, 18 (5.7%) single-arm trials had PFS as a primary or 
co-primary outcome. 
The randomized comparative trials on average analyzed approximately three times 
as many patients (median = 131, IQR = 89, 182) as single-arm trials (median = 43, IQR = 34, 
58), exemplifying an ability in many circumstances to overcome concerns around increased 
requisite sample sizes (Table 2). Additionally, though there is evidence that different type-I 
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error-rates have been used across the four design types (Kruskal-Wallis test, P = 0.04; see 
Table 2 and Supplementary Figures 1-2), the lower-quartile, median, and upper-quartile 
values used in the single-arm and randomized comparative trials are equal, suggesting calls 
for randomized comparative trials to utilize increased error-rates may not have been 
realized in the way many authors desired. 
Importantly, Table 2 highlights that amongst the trials which reported a conclusion, 
the analyzed randomized comparative trials less frequently come to positive conclusions 
(29/103 trials, 28.2%) than single-arm (152/209, 72.7%), multi-arm non-randomized (25/30, 
82.3%), and randomized non-comparative trials (39/55, 70.9%). This, in particular, raises 
concerns over the choice of historical controls, and specification of the hypotheses, in the 
single-arm trials. 
Finally, in Table 3 we observe that more than 50% of cytotoxic, combination, and 
targeted therapy trials have utilized either tumor response, PFS, or a dichotomized version 
of PFS, as a primary or co-primary outcome, with tumor response the most commonly 
utilized endpoint for all three treatment types. Also, perhaps surprisingly given previous 
recommendations, tumor response was used more than twice as often as PFS for targeted 
therapies. 
 
Contemporary factors influencing phase II design 
Whilst the use of randomized designs in phase II has increased, an open question exists as to 
what this has taught us about randomization’s applicability, particularly given it does not 
appear to have improved success rates in phase III [81]. Furthermore, whilst there has been 
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much interest in the use of novel endpoints, this has not materialized in the way many 
hoped it would [82]. We may therefore still question whether poor performance in phase III 
is down to the methods typically used in phase II. Careful design choice in phase II thus 
remains paramount. In addition, several contemporary articles highlight additional 
important considerations for future phase II trials. 
Firstly, despite historical agreement on the suitability of single-arm designs for rare 
cancers, whether this should be universally accepted has recently been challenged [83,84]. It 
has been argued that the field of oncology performs a disservice to patients with rare 
tumors when we accept medications using inferior levels of evidence. It has also been 
maintained that whilst randomized trials are difficult to conduct in rare tumors, large 
randomized trials have been conducted for even ultra-rare tumors, providing reliable results 
to important questions [83]. Thus, randomization has more to do with our expectations than 
tumor incidence. Accordingly, we should not accept that randomization is not required for 
rare conditions. Whether randomization can, and will, be more commonly utilized in rare 
cancer types remains to be seen. 
Moreover, in recent years, there has been increased interest in the use of novel 
adaptive designs in phase II, such as umbrella and basket designs [85]. How this complicates 
the debate on the use of randomization, and the preferred primary endpoint, remains 
unclear. Many of the available adaptive designs applicable in phase II are non-randomized in 
nature, yet one may expect that adaptation might improve trial efficiency in a way that 
randomization becomes more feasible. Furthermore, adaptive designs typically require a 
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djz126/5520955 by C
ardiff U
niversity user on 23 July 2019
primary outcome that can be evaluated quickly. This implies that PFS, which has been much 
argued for historically, may be difficult to utilize with such designs. 
Perhaps most important are considerations around the design of trials that utilize 
biomarkers, given their evident increased use [80]. It has long been argued that 
randomization would be needed for biomarker-guided trials, not only as historical data 
would be unavailable, but also because of the requirement to validate the biomarker as a 
predictive marker of efficacy [33,86-88]. However, it has been pointed out that conducting 
randomized trials in pre-specified subgroups with very low frequency biomarkers may be 
difficult [89], and that randomized assignment may be unnecessary if tumor shrinkage is the 
primary endpoint, as only predictive factors would be expected to correlate with shrinkage 
[37]. 
This debate is further complicated by the emergence of several drugs with extremely 
high response rates in novel biomarker-guided patient subgroups. Given these remarkable 
response rates, it has been argued that randomized trials may be unnecessary and 
unjustifiable on ethical grounds [69,90]. However, it has been noted that this remains an 
extremely unusual situation [33,89,91]. Thus, only in rare cases would it be unethical to 
randomize, and we should not let such findings guide our overall development strategy 
[33,88], with several authors even advocating for randomized designs to be used more often 
in phase I [88,92]. Nevertheless, Selaru et al. describe a variety of settings in which dramatic 
activity would be enough to license a monotherapy MTA on the basis of a single-arm trial 
[93]. So too has Simon et al. described the potential future role of tumor response as a basis 
for licensing [72]. They emphasize, though, that the utilization of classical phase II designs 
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remains reliant on the choice of historical controls. Thus, guidelines from regulatory bodies 
on how to achieve appropriate use of historical comparator groups will be paramount to 
future trials. 
 
Discussion 
Many years have now passed since the beginnings of the debate on optimal phase II 
oncology trial design and yet it remains a subject of on-going deliberation (see, e.g., 
Grossman et al. [94] for a recent examination in the context of glioblastoma). Furthermore, 
whilst this debate has contributed to an increase in the number of randomized phase II 
trials, phase II design for cytotoxic and targeted therapies remains similar, and we remain 
without evidence that the use of randomized designs in phase II has improved outcomes in 
phase III. 
Little has changed in terms of the importance of resolving this debate. Accordingly, 
all new guidance on phase II oncology trial design remains extremely valuable. Such 
guidance will be key to the effectual design of future studies. 
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Tables 
 
Table 1. A summary of the key arguments/counterpoints that have historically been put forward 
for and against the use of randomization in phase II oncology trials 
Consideration For randomization Against randomization 
Molecularly targeted agents may 
often be cytostatic, and not in 
general lead to tumor shrinkage. 
Progression free-survival should 
be the preferred primary 
outcome for cytostatic agents, 
which in turn makes 
randomization preferable. 
The use of tumor response is still 
appropriate, as several cytostatic 
agents have led to statistically 
significant tumor regression. 
Success in phase II should reliably 
predict that clinical benefit will be 
observed in phase III. 
The classical single-arm paradigm 
has performed poorly in 
predicting clinical benefit in phase 
III; randomized designs would 
perform better. 
No evidence is available to 
suggest the use of randomization 
in phase II has improved success 
in phase III. 
Randomized phase II designs 
appear more similar to phase III 
designs, than conventional phase 
II designs. 
A highly statistically significant p-
value from a randomized trial 
would provide a strong case for 
seeking regulatory approval. 
Investigators may incorrectly 
interpret the results of 
randomized phase II trials as 
though they are from a large 
phase III study. 
Single-arm trials use historical 
control data to specify their 
design. 
Reliance on historical control data 
for setting target response makes 
the results of single-arm trials 
unreliable. 
For several diseases well-
established resources do allow for 
the determination of the 
historical response to treatment. 
Prognostic factors can differ 
substantially between patients, 
and these are often strong 
predictors of response to 
treatment. 
Randomization should balance 
prognostic factors between arms, 
allowing for a more reliable 
assessment of efficacy. Attempts 
to account for such covariates in 
single-arm data using modelling 
are unreliable. 
Randomization cannot guarantee 
prognostic factors will be 
balanced, especially in smaller 
trials, and modelling can be used 
to account for such variables in 
single-arm studies. 
There is a trade-off between trial 
complexity and quality. 
In conducting a randomized trial, 
you ‘get what you pay for’, with 
better quality data accrued. 
Single-arm trials are simpler and 
easier to conduct. 
Clinical trials should be conducted 
with as few participants as are 
required to control type-I/II error-
rates to specified levels. 
One-sided testing with increased 
type-I/II error-rates allows 
randomized trials to be 
conducted with achievable 
sample sizes. Only in a 
randomized trial are these error-
rates ever known. 
Single-arm trials require a much 
smaller sample size and modifying 
error-rates to reduce that 
required by a randomized trial 
would only increase failure in 
phase III. 
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Single-arm designs should be 
preferred from an ethical 
standpoint. 
In general, there is equipoise, 
making randomized trials entirely 
appropriate. 
Randomized trials are not ethical 
when large responses have been 
observed previously, as not all 
participants have access to a 
potentially better treatment. Dow
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Table 2. A summary of the characteristics (e.g., treatment type, primary/co-primary endpoint, 
patients analyzed) of phase II oncology trials by type of design used (e.g., single-arm, 
randomized non-comparative), based on a re-analysis of the data from Langrand-Escure et al. 
[80]* 
Characteristic 
Single-arm, 
% (IQR) 
Multi-arm non-
randomized, % 
(IQR) 
Randomized non-
comparative, % 
(IQR) 
Randomized 
comparative, 
% (IQR) 
P-
value† 
Type of therapy      
Cytotoxic 84 (26.7) 13 (26.5) 24 (31.6) 27 (23.1) 0.02 
Combination 
therapy 
102 (32.4) 11 (22.4) 27 (35.5) 53 (45.3) 
Targeted therapy 62 (19.7) 17 (34.7) 8 (10.5) 16 (13.7) 
Other 67 (21.3) 8 (16.3) 17 (22.4) 21 (17.9) 
(Co-)Primary 
endpoint‡ 
     
Tumor response 129 (41.0) 18 (36.7) 26 (34.2) 18 (15.4) – 
Dichotomized PFS 23 (7.3) 6 (12.2) 9 (11.8) 5 (4.3) 
PFS 18 (5.7) 1 (2.0) 5 (6.6) 47 (40.2) 
Other 159 (50.5) 26 (53.1) 38 (50.0) 54 (46.2) 
Positive result 152 (72.7) 25 (83.3) 39 (70.9) 29 (28.2) < 0.001 
Median type-I error-
rate (IQR) 
5 (5-10) 5 (5-10) 7.1 (5-10) 5 (5-10) 0.04 
Median type-II error-
rate (IQR) 
14 (10-20) 10 (9.8-12.5) 10 (10-20) 20 (15-20) < 0.001 
Median patients 
analyzed (IQR) 
43 (34-58) 72.5 (49.8-111) 92 (72.8-135) 131 (89-182) < 0.001 
* Note that the dataset from Langrand-Escure et al. [80] comprises 557 trial reports.  
† In addition, P-values for either a chi-squared test of row-column independence or a Kruskal-Wallis 
test of stochastic dominance, as appropriate, are reported for each of the characteristics. All 
statistical tests were two-sided. 
‡ The percentages for the (co-)primary characteristic section do not add up to 100% because the 
categories are not mutually exclusive given the allowance for co-primary endpoints, and 
consequently a P-value is omitted for this section. 
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Table 3. A summary of the choices of primary/co-primary endpoints (e.g., tumor response) in 
phase II by the type of treatment under investigation (e.g., cytotoxic), based on a re-analysis of the 
data from Langrand-Escure et al. [80]* 
(Co-)Primary endpoint Cytotoxic 
No. (%) 
Combination therapy 
No. (%) 
Targeted therapy 
No. (%) 
Tumor response 69 (46.6) 53 (27.5) 35 (34.0) 
Dichotomized PFS 5 (3.4) 18 (9.3) 16 (15.5) 
PFS 10 (6.8) 38 (19.7) 16 (15.5) 
Other 67 (45.3) 92 (47.7) 44 (42.7) 
* The percentages do not add up to 100% because the categories are not mutually exclusive given 
the allowance for co-primary endpoints. 
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Box 1. A summary of the key findings, in light of historical recommendations, from the re-analysis 
of the data from Langrand-Escure et al. [80] 
Finding 
102 (32.4%) of the single-arm trials were of combination therapies. 
47 (66.2%) of the trials employing progression-free survival as a primary or co-primary outcome used 
randomized comparative designs. 
18 (5.7%) of the single-arm trials used progression-free survival as a primary or co-primary outcome. 
The median number of patients analyzed in the randomized comparative trials was 131, compared to 
43 for the single-arm trials. 
29 (28.2%) of the randomized comparative trials came to a positive conclusion, compared to 152 
(72.7%) of the single-arm trials. 
More than 50% of the trials of cytotoxic, combination, and targeted therapies utilized either tumor 
response, PFS, or a dichotomized version of progression-free survival as a primary or co-primary 
outcome. 
35 (34%) of the trials of targeted therapies used tumor response as a primary or co-primary outcome, 
whilst 16 (15.5%) used progression-free survival. 
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